Oral anti-CD3 MAb Immunization / Immunotherapy – Clinical proof of principle

In R&D by Freya SmaleLeave a Comment

Oral CD3

Oral anti-CD3 MAb Immunization / Immunotherapy – Clinical proof of principle

Dr Ronald Ellis, Senior Vice President, Research & Development and Chief Technology Officer, NasVax joined us at the World Vaccine Congress Lyon 2012 to give a presentation on the clinical proof of principle of Oral anti-CD3 MAb Immunization/Immunotherapy. With focus on the following, this presentation provides all the information you need to find out more about the use of Oral anti-CD3 MAb Immunization / Immunotherapy:

  • Oral anti-CD3 MAb immunization – Clinical proof of principle
  • Oral administration results in the induction of regulatory T cells for alleviating inflammatory and autoimmune diseases with excellent safety
  • Phase 2a clinical study in subjects with NASH (fatty liver disease) and altered glucose metabolism (some with T2D) showed favourable changes in clinical biomarkers for hepatitis and glucose metabolism
  • First monoclonal antibody administered by oral route in clinical trials.


Download the presentation here >

For more information about this and other topics discussed at the World Vaccine Congress Lyon, subscribe to the Vaccine Nation newsletter, or visit the event website.

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *